TICKERNERD
Menu
IDXXIDXXHealthcare · Diagnostics & Research

IDXX Stock Forecast: IDEXX Laboratories, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$551
−2.82% on the day

The 14 Wall Street analysts covering IDEXX Laboratories, Inc. hold a median 12-month price target of $700 — +27.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$43.4B
Ticker Nerd rank
93 / 100
Median analyst target
$700
Analysts covering
14
Total return, dividends reinvested
1W
−6.1%
1M
+1.9%
YTD
−18.6%
1Y
−15.7%
From 52W high
−28.1%
From 52W low
+4.7%
$526
$767
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IDXX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores IDEXX Laboratories, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Issuance
97
Volatility
90
Value
84
Revisions
75
Growth
68
Momentum
58
Accruals
56
Size
6

Quality (99): The business earns solid, repeatable profits on what it owns.

Accruals (56): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IDXX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IDXX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$400$500$600$700$800Oct 25Jan 26Apr 26Jul 26IDXXHigh $805Median $700Low $470

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts
8 Buy5 Hold1 Sell
Low $470Median $700High $805

The green dot is the last close — the median target sits +27.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
11 Aug 2026BarclaysMaintainsOverweight$800 → $710
5 Aug 2026CitigroupMaintainsNeutral$650 → $670
5 Aug 2026UBSMaintainsNeutral$620 → $670
27 July 2026UBSMaintainsNeutral—
27 July 2026UBSMaintainsNeutral$640 → $620
28 Apr 2026UBSMaintainsNeutral$730 → $640
28 Apr 2026UBSMaintainsNeutral—
15 Apr 2026CitigroupInitiatesNeutral—
31 Mar 2026StifelMaintainsBuy—
9 Feb 2026Piper SandlerMaintainsNeutral—
5 Feb 2026BarclaysMaintainsOverweight—
3 Feb 2026BTIGMaintainsBuy—
3 Feb 2026UBSMaintainsNeutral—
9 Dec 2025BarclaysInitiatesOverweight—
4 Nov 2025BTIGMaintainsBuy—
4 Nov 2025JP MorganMaintainsOverweight—
4 Nov 2025Morgan StanleyMaintainsOverweight—
4 Nov 2025UBSMaintainsNeutral—
31 Oct 2025StifelUpgradeBuy—
1 Oct 2025UBSInitiatesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IDXX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

IDXX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.0%
Analysts raising
2
Analysts cutting
1
Fundamentals

IDEXX Laboratories, Inc. (IDXX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
38.8×

Cheaper than 20% of US stocks

Price / sales
9.5×

Cheaper than 15% of US stocks

Price / book
26.9×

Cheaper than 4% of US stocks

EV / EBITDA
27.3×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
9.7%

Higher than 52% of US stocks

Earnings growth (YoY)
15.1%

Higher than 54% of US stocks

Gross margin
64.0%

Higher than 78% of US stocks

Operating margin
35.0%

Higher than 89% of US stocks

Net margin
25.0%

Higher than 86% of US stocks

Returns & dividend
Return on equity
74.2%

Higher than 95% of US stocks

Return on assets
27.1%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IDXX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
IDXXIDEXX Laboratories, Inc.$43.4B
93
NTRANatera, Inc.$42.8B
79
AAgilent Technologies, Inc.$42.1B
88
WATWaters Corp.$40.4B
49
IQVIQVIA Holdings, Inc.$39.0B
92
ILMNIllumina, Inc.$29.3B
96
MTDMettler-Toledo International, Inc.$29.0B
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own IDEXX Laboratories, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IDXX news & analysis

IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests

MarketBeat · 14 Aug 2026positive

IDEXX Laboratories presented its growth strategy at its 2026 Investor Day, focusing on a $45 billion global companion-animal testing opportunity and a pipeline of diagnostic, software, and AI offerings to boost testing utilization in veterinary practices.

Why it matters — An IDXX watcher would care because the company laid out a clear innovation-led growth plan targeting a massive addressable market, signaling potential for expanded commercial investment and new revenue streams from AI and cancer diagnostics.

Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock

Zacks Investment Research · 12 Aug 2026positive

Zacks Investment Research highlighted Idexx Laboratories (IDXX) as a strong growth stock, noting that the Zacks Style Scores system helps investors identify top-rated stocks based on investing style.

Why it matters — A positive assessment from Zacks could attract attention from growth-focused investors monitoring IDXX.

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

Business Wire · 11 Aug 2026positive

IDEXX announced the Catalyst proBNP Test, described as the first and only dual-species, in-clinic diagnostic assay for cardiac assessment, expanding its Catalyst platform into cardiac disease.

Why it matters — This extends IDEXX's point-of-care diagnostics into a new cardiac testing area, potentially broadening its in-clinic product lineup for veterinarians.

IDEXX Laboratories: Worth The Premium

Seeking Alpha · 8 Aug 2026positive

Seeking Alpha coverage of IDEXX Laboratories describes the company as retaining a durable moat with strong recurring revenue and a long-term international growth runway. Recent Q2 2026 results showed 9% organic revenue growth, raised EPS guidance to $14.69–14.94, and robust expansion of diagnostic offerings, with US installed-base growth moderating while international expansion remains early-stage.

Why it matters — A stock-research watcher of IDEXX would care because the piece highlights sustained organic growth and an early-stage international installed-base opportunity that could underpin multi-decade expansion beyond the moderating US market.

Here is Why Growth Investors Should Buy Idexx (IDXX) Now

Zacks Investment Research · 6 Aug 2026positive

Zacks Investment Research published an article highlighting Idexx Laboratories' solid growth attributes, stating the company could produce exceptional returns as a result of these characteristics.

Why it matters — The piece frames IDXX's growth attributes more positively, which IDXX watchers would care about given the company's positioning in the market.

FAQ

Frequently asked questions about IDXX stock

What is the IDXX stock price forecast for 2026-2027?

The 14 Wall Street analysts covering IDEXX Laboratories, Inc. have a median 12-month price target of $700, with estimates ranging from $470 to $805. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IDXX stock a buy right now?

Of the 14 analysts covering IDEXX Laboratories, Inc., 8 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks IDEXX Laboratories, Inc. 93 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IDXX?

As at 15 Aug 2026, IDEXX Laboratories, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will IDXX stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +27.1% from the last close, and Ticker Nerd's factor model ranks IDEXX Laboratories, Inc. 93 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IDXX stock forecast for 2030?

No analyst covering IDEXX Laboratories, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IDXX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $470 to $805 over the next 12 months.

How has IDXX stock performed over the past year?

IDEXX Laboratories, Inc. returned -15.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IDEXX Laboratories, Inc. do?

IDEXX Laboratories, Inc. is a healthcare diagnostics company specializing in products and services for the veterinary, livestock, poultry, dairy, and water testing markets.

What is the latest news on IDXX?

The most recent item we track (MarketBeat, 14 Aug 2026): "IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests". IDEXX Laboratories presented its growth strategy at its 2026 Investor Day, focusing on a $45 billion global companion-animal testing opportunity and a pipeline of diagnostic, software, and AI offerings to boost testing utilization in veterinary practices.

Company

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a healthcare diagnostics company specializing in products and services for the veterinary, livestock, poultry, dairy, and water testing markets. The company develops and manufactures diagnostic test kits, in-clinic analyzers, and reference laboratory services that support veterinarians in diagnosing and monitoring health conditions in companion animals. IDEXX Laboratories, Inc. also provides management software, digital imaging systems, and data analytics tools that help veterinary practices streamline workflows and clinical decision-making. Beyond companion animals, the company offers testing solutions for livestock and poultry health, dairy quality, and water microbiology, supporting food safety and public health monitoring. Its operations are organized into segments including Companion Animal Group, Water, Livestock, Poultry, and Dairy, and other related services. Founded in 1983 and headquartered in Westbrook, Maine, IDEXX Laboratories, Inc. plays a significant role in modern animal health diagnostics and environmental testing worldwide.

CEO Mr. Michael G. Erickson Ph.D. · 11,000 employees · United States · https://www.idexx.com